drugset / Trial / NCT00074711
Adding Phosphorus to Osteoporosis Drug Treatment
Phase 2
Completed
241 enrolled
Creighton University
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collabOffice of Dietary Supplements (ODS) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Osteoporosis causes bones to weaken and break more easily. Calcium and phosphorus are two minerals that are essential for normal bone formation. Unfortunately, calcium salts commonly prescribed in anti-osteoporosis treatment bind phosphorus from food and restrict phosphorus available for bone building. Teriparatide is a drug that reduces the risk of fractures by increasing bone thickness and strength. Vitamin D is also necessary for strong bones and teeth. The purpose of this study is to evaluate the bone-building effectiveness of two calcium supplements, one with a source of phosphorus and one without, in combination with teriparatide and vitamin D in women with osteoporosis.
Timeline
- Start
- 2004-08
- Primary completion
- 2008-06
- Completion
- 2008-06
Publications
- Results Heaney RP, Recker RR, Watson P, Lappe JM. Phosphate and carbonate salts of calcium support robust bone building in osteoporosis. Am J Clin Nutr. 2010 Jul;92(1):101-5. doi: 10.3945/ajcn.2009.29085. Epub 2010 May 19.
- Heaney RP, Watson P. Variability in the measured response of bone to teriparatide. Osteoporos Int. 2011 Jun;22(6):1703-8. doi: 10.1007/s00198-010-1376-1. Epub 2010 Sep 9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Calcium Phosphate | Unknown | — | — |
| Comparator | Calcium carbonate | Other / unclassified | — | — |